Stifel Have $85.0 Target On Ascendis Pharma (ASND).

June 27, 2018 - By Anthony Rauscher

What Price Target Has Stifel Given Ascendis Pharma (ASND)

EU: On Tuesday, 26 June, Ascendis Pharma (ASND) coverage was initiated with a “Buy” rating and $85.0 PT at Stifel. That’s upside potential of 150.15 % from company’s previous stock close.

ASND is touching $67.37 during the last trading session, after increased 2.25%.Ascendis Pharma A/S is uptrending after having risen 178.35% since June 27, 2017. ASND has 182,366 volume or 51.01% up from normal. ASND outperformed by 165.78% the S&P 500.

On August, 17 is anticipated Ascendis Pharma A/S (NASDAQ:ASND)’s earnings report, according to Faxor. Analysts predict $-0.96 EPS, which is $0.08 up or 7.69 % from 2017’s $-1.04 EPS. Wall Street forecasts -26.72 % EPS growth as of August, 17.

Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies for unmet medical needs.The firm is worth $2.80 billion. The firm develops TransCon human growth hormone, which is in Phase III clinical study in children to treat growth hormone deficiency; TransCon parathyroid hormone that is in Phase I clinical study for treating hypoparathyroidism; and TransCon C-type natriuretic peptide for the treatment of achondroplasia.Currently it has negative earnings. It also has strategic collaborations with Sanofi to develop TransCon Peptides for the treatment of diabetes; and Genentech and Roche to develop TransCon anti-vascular endothelial growth factor , a compound to support injection of anti-VEGF in ophthalmology.

For more Ascendis Pharma A/S (NASDAQ:ASND) news posted briefly go to: Benzinga.com, Globenewswire.com, Benzinga.com, Nasdaq.com or 247Wallst.com. The titles are as follows: “Benzinga’s Top Upgrades, Downgrades For June 26, 2018” posted on June 26, 2018, “Ascendis Pharma A/S Reports First Quarter 2018 Financial Results” on May 30, 2018, “Ascendis Will Rise Higher On ‘Game-Changing’ TransCon Technology, Stifel Says In Bullish Initiation” with a publish date: June 26, 2018, “Ascendis Pharma Announces Orphan Drug Designation Granted for TransCon PTH as Treatment for Hypoparathyroidism” and the last “Biopharma Companies to Watch This Week” with publication date: June 24, 2018.

Ascendis Pharma A/S (NASDAQ:ASND) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.